Key facts
- This page summarizes Stuart Holden's Form 4 filing for UroGen Pharma Ltd. (URGN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Jun 2026, 10:01.
Stuart Holden - 22 Jun 2026 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)
- Reporting relationship
- Director
- Issuer ticker
- URGN
- Reported as of
- 22 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2026, 10:01:21 UTC
- Prior SEC filing
- 01 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason D. Smith, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stuart Holden filed Form 4 for UroGen Pharma Ltd. (URGN) on 24 Jun 2026.
Change
- Previous filing in this sequence was filed on 01 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001763999
Primary reporting owner
Holden Stuart
- Relationship
- Director
- Address
- 400 ALEXANDER PARK DRIVE, PRINCETON
- Signature
- /s/ Jason D. Smith, Attorney-in-Fact
- Signature date
- 23 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
URGN
transaction
Derivative
Stock Option (right ot buy)
Award
- Transaction value
- Shares
- +20,000
- Change %
- Price
- $0.000000*
- Shares after
- 20,000
- Date
- 22 Jun 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 20,000
- Exercise price
- $34.99
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.